Background: Pembro þ D þ T had promising antitumor activity and acceptable tolerability in phase 1 of KEYNOTE-022 (NCT02130466) . Methods: In the double-blind phase 2 part of KEYNOTE-022, pts with treatment (tx)-naive BRAF V600E/K -mutant stage III/IV melanoma were randomly assigned (stratified by ECOG PS [0/1)]; LDH level [>1.1 vs 1.1Â ULN]) to pembro 2 mg/kg Q3W þ D 150 mg BID þ T 2 mg QD or PBO þ D þ T. Strata with ECOG PS 1 and either LDH level were combined due to small numbers. Primary end point was PFS. Significance requirements to reject null hypothesis at 1-sided 0.025 type I error: $74 PFS events for 80% power; observed HR 0.62. Additional end points included ORR, DOR, TTR, and OS. Data cutoff: Feb 15, 2018. Results: Of 60 pts in each arm, most baseline characteristics were balanced (stage IV disease, 98% in pembro þ D þ T vs 95% in PBO þ D þ T; ECOG PS 0, 80% both; LDH >1.1Â ULN, 45% vs 43%). Median follow-up for both arms was 9.6 mo (range 2.7-23.4). 67% vs 70% received !12 mo tx. Median PFS was 16.0 mo (95% CI 8.6-21.5) with pembro þ D þ T vs 10.3 mo (95% CI 7.0-15.6) with PBO þ D þ T; HR, 0.66; P ¼ 0.04287; 12-mo PFS rates were 59% vs 45%. ORR was 63% vs 72%; CR rates were 18% vs 13%. Median TTR was 2.8 mo in each arm; median DOR was 18.7 mo (range 1.9þ to 22.1) vs 12.5 (2.1-19.5þ). More patients (60%) on pembro þ D þ T had responses lasting !18 mo vs PBO þ D þ T (28%). OS rates at 12 mo were 80% vs 73%. Any grade (G) treatment-related AEs (TRAEs) occurred in 95% vs 93% and G3-5 TRAEs occurred in 58% vs 27% of pts. G3-5 TRAEs occurring in ! 5% of pts were pyrexia (10% vs 3%), increased ALT (7% vs 5%), increased AST (8% vs 5%), increased GGT (7% vs 5%), rash (5% vs 2%), and neutropenia (2% vs 5%). 40% vs 20% of pts discontinued any of the 3 study tx due to TRAEs, and 1 pt died due to a TRAE (pneumonitis) in the pembro þ D þ T arm. Immune-mediated AEs occurred in 43% vs 13% of pts, most commonly pneumonitis (15% vs 2%), hypothyroidism (8% vs 2%), skin disorders (7% vs 2%), hyperthyroidism (5% vs 0%), and uveitis (5% vs 3%); most resolved with tx discontinuation/modification. Methods: The study will enroll up to 60 pts with rMM to receive IT (with/without IG) tilsotolimod (scheduled weeks 1,2,3,5,8,11,17, 23 and 29) ; ipi is given per the product label starting at week 2. Pts with M1c disease, mucosal melanoma and BRAF mutations were included. The primary endpoint is RECIST1.1 objective response rate (ORR); other endpoints are safety and tolerability and disease control rate (DCR). Immune analyses of T-cell repertoire diversity evaluated by high-throughput CDR3 sequencing. Phase 2 accrual is ongoing. Results: As of 9 Apr 2018, 26 pts have been treated with tilsotolimod 8mgþ ipi, including 5 pts who received IG injections to deep visceral lesions or lymph nodes. Median age: 65.8 (range 39-91 yrs); 11 IVM1c. 6 pts had irAEs [hypophysitis (2), hepatitis (2), adrenal insufficiency (1), Guillain-Barre syndrome (1), colitis (1), enterocolitis (1)], which responded to standard measures. Injection-related toxicities were grade 1-2 transient fever and flu like symptoms lasting <48 hours. Major expanding T-cell clones are found to be shared in responding local and distant lesions indicating that reactivation is to a shared antigen in responding patients. As of 9 May 2018, 21 pts were assessed for response: 38% ORR and 71% DCR (2 CR, 6 PR, 7 SD). 6 of 8 responses are ongoing including 1 CR > 23 mo. 10 pts had BRAF mutations (1 CR, 3 PR, and 4 SD). Conclusions: IT tilsotolimod 8mgþ ipi is well tolerated and shows substantial clinical benefit and durable responses. The ORR of 38% compares favorably to ipi in this challenging population, leading to an ongoing global randomized Phase 3 study of tilsotolimod 8mgþipi vs. ipi in aPD-1 rMM. Clinical trial identification: NCT02644967. Legal entity responsible for the study: Idera Pharmaceuticals. Funding: Idera Pharmaceuticals. Disclosure: All authors have declared no conflicts of interest. 
